Associations - Loqtorzi (toripalimab-tpzi)

No biomarker	Nasopharyngeal Carcinoma	No biomarker	Nasopharyngeal Carcinoma	toripalimab-tpzi Sensitive: A1 - Approval toripalimab-tpzi Sensitive : A1	toripalimab-tpzi Sensitive: A1 - Approval toripalimab-tpzi Sensitive : A1
No biomarker	Urothelial Cancer	No biomarker	Urothelial Cancer	toripalimab-tpzi Sensitive: A1 - Approval toripalimab-tpzi Sensitive : A1	toripalimab-tpzi Sensitive: A1 - Approval toripalimab-tpzi Sensitive : A1
No biomarker	Lung Non-Squamous Non-Small Cell Cancer	No biomarker	Lung Non-Squamous Non-Small Cell Cancer	toripalimab-tpzi Sensitive: A1 - Approval toripalimab-tpzi Sensitive : A1	toripalimab-tpzi Sensitive: A1 - Approval toripalimab-tpzi Sensitive : A1
No biomarker	Mucosal Melanoma	No biomarker	Mucosal Melanoma	toripalimab-tpzi Sensitive: B - Late Trials toripalimab-tpzi Sensitive : B	toripalimab-tpzi Sensitive: B - Late Trials toripalimab-tpzi Sensitive : B
PD-L1 expression	Triple Negative Breast Cancer	PD-L1 expression	Triple Negative Breast Cancer	toripalimab-tpzi Sensitive: B - Late Trials toripalimab-tpzi Sensitive : B	toripalimab-tpzi Sensitive: B - Late Trials toripalimab-tpzi Sensitive : B
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	toripalimab-tpzi Sensitive: B - Late Trials toripalimab-tpzi Sensitive : B	toripalimab-tpzi Sensitive: B - Late Trials toripalimab-tpzi Sensitive : B
ALK wild-type	Non Small Cell Lung Cancer	ALK wild-type	Non Small Cell Lung Cancer	toripalimab-tpzi Sensitive: B - Late Trials toripalimab-tpzi Sensitive : B	toripalimab-tpzi Sensitive: B - Late Trials toripalimab-tpzi Sensitive : B
No biomarker	Non Small Cell Lung Cancer	No biomarker	Non Small Cell Lung Cancer	toripalimab-tpzi Sensitive: B - Late Trials toripalimab-tpzi Sensitive : B	toripalimab-tpzi Sensitive: B - Late Trials toripalimab-tpzi Sensitive : B
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	toripalimab-tpzi + axitinib Sensitive: B - Late Trials toripalimab-tpzi + axitinib Sensitive : B	toripalimab-tpzi + axitinib Sensitive: B - Late Trials toripalimab-tpzi + axitinib Sensitive : B
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	toripalimab-tpzi Sensitive: B - Late Trials toripalimab-tpzi Sensitive : B	toripalimab-tpzi Sensitive: B - Late Trials toripalimab-tpzi Sensitive : B
PD-L1 expression	Urothelial Cancer	PD-L1 expression	Urothelial Cancer	toripalimab-tpzi Sensitive: C2 – Inclusion Criteria toripalimab-tpzi Sensitive : C2	toripalimab-tpzi Sensitive: C2 – Inclusion Criteria toripalimab-tpzi Sensitive : C2
TMB-H	Gastric Cancer	TMB-H	Gastric Cancer	toripalimab-tpzi Sensitive: C2 – Inclusion Criteria toripalimab-tpzi Sensitive : C2	toripalimab-tpzi Sensitive: C2 – Inclusion Criteria toripalimab-tpzi Sensitive : C2
POLE mutation	Solid Tumor	POLE mutation	Solid Tumor	toripalimab-tpzi Sensitive: C2 – Inclusion Criteria toripalimab-tpzi Sensitive : C2	toripalimab-tpzi Sensitive: C2 – Inclusion Criteria toripalimab-tpzi Sensitive : C2
POLD1 mutation	Solid Tumor	POLD1 mutation	Solid Tumor	toripalimab-tpzi Sensitive: C2 – Inclusion Criteria toripalimab-tpzi Sensitive : C2	toripalimab-tpzi Sensitive: C2 – Inclusion Criteria toripalimab-tpzi Sensitive : C2
PD-L1 expression	Neuroendocrine Tumor	PD-L1 expression	Neuroendocrine Tumor	toripalimab-tpzi Sensitive: C2 – Inclusion Criteria toripalimab-tpzi Sensitive : C2	toripalimab-tpzi Sensitive: C2 – Inclusion Criteria toripalimab-tpzi Sensitive : C2
EGFR mutation	Non Small Cell Lung Cancer	EGFR mutation	Non Small Cell Lung Cancer	toripalimab-tpzi Sensitive: C2 – Inclusion Criteria toripalimab-tpzi Sensitive : C2	toripalimab-tpzi Sensitive: C2 – Inclusion Criteria toripalimab-tpzi Sensitive : C2
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	toripalimab-tpzi Sensitive: C2 – Inclusion Criteria toripalimab-tpzi Sensitive : C2	toripalimab-tpzi Sensitive: C2 – Inclusion Criteria toripalimab-tpzi Sensitive : C2
PD-L1 expression	Esophageal Squamous Cell Carcinoma	PD-L1 expression	Esophageal Squamous Cell Carcinoma	toripalimab-tpzi Sensitive: C2 – Inclusion Criteria toripalimab-tpzi Sensitive : C2	toripalimab-tpzi Sensitive: C2 – Inclusion Criteria toripalimab-tpzi Sensitive : C2
PD-L1 expression	Melanoma	PD-L1 expression	Melanoma	toripalimab-tpzi + axitinib Sensitive: C2 – Inclusion Criteria toripalimab-tpzi + axitinib Sensitive : C2	toripalimab-tpzi + axitinib Sensitive: C2 – Inclusion Criteria toripalimab-tpzi + axitinib Sensitive : C2
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	bevacizumab + toripalimab-tpzi Sensitive: C2 – Inclusion Criteria bevacizumab + toripalimab-tpzi Sensitive : C2	bevacizumab + toripalimab-tpzi Sensitive: C2 – Inclusion Criteria bevacizumab + toripalimab-tpzi Sensitive : C2
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	toripalimab-tpzi Sensitive: C2 – Inclusion Criteria toripalimab-tpzi Sensitive : C2	toripalimab-tpzi Sensitive: C2 – Inclusion Criteria toripalimab-tpzi Sensitive : C2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	toripalimab-tpzi Sensitive: C2 – Inclusion Criteria toripalimab-tpzi Sensitive : C2	toripalimab-tpzi Sensitive: C2 – Inclusion Criteria toripalimab-tpzi Sensitive : C2
PD-L1 expression	Nasopharyngeal Carcinoma	PD-L1 expression	Nasopharyngeal Carcinoma	toripalimab-tpzi Sensitive: C2 – Inclusion Criteria toripalimab-tpzi Sensitive : C2	toripalimab-tpzi Sensitive: C2 – Inclusion Criteria toripalimab-tpzi Sensitive : C2
ATM mutation	Biliary Tract Cancer	ATM mutation	Biliary Tract Cancer	toripalimab-tpzi Resistant: C3 – Early Trials toripalimab-tpzi Resistant : C3	toripalimab-tpzi Resistant: C3 – Early Trials toripalimab-tpzi Resistant : C3
DDR	Cholangiocarcinoma	DDR	Cholangiocarcinoma	lenvatinib + toripalimab-tpzi Sensitive: C3 – Early Trials lenvatinib + toripalimab-tpzi Sensitive : C3	lenvatinib + toripalimab-tpzi Sensitive: C3 – Early Trials lenvatinib + toripalimab-tpzi Sensitive : C3
PD-L1 expression	Cholangiocarcinoma	PD-L1 expression	Cholangiocarcinoma	lenvatinib + toripalimab-tpzi Sensitive: C3 – Early Trials lenvatinib + toripalimab-tpzi Sensitive : C3	lenvatinib + toripalimab-tpzi Sensitive: C3 – Early Trials lenvatinib + toripalimab-tpzi Sensitive : C3
TMB-H	Neuroendocrine Tumor	TMB-H	Neuroendocrine Tumor	toripalimab-tpzi Sensitive: C3 – Early Trials toripalimab-tpzi Sensitive : C3	toripalimab-tpzi Sensitive: C3 – Early Trials toripalimab-tpzi Sensitive : C3
PD-L1 expression	Melanoma	PD-L1 expression	Melanoma	toripalimab-tpzi Sensitive: C3 – Early Trials toripalimab-tpzi Sensitive : C3	toripalimab-tpzi Sensitive: C3 – Early Trials toripalimab-tpzi Sensitive : C3
PD-L1 underexpression	Gastric Adenocarcinoma	PD-L1 underexpression	Gastric Adenocarcinoma	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3
PD-L1 underexpression	Esophageal Squamous Cell Carcinoma	PD-L1 underexpression	Esophageal Squamous Cell Carcinoma	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3	toripalimab-tpzi + surufatinib Sensitive: C3 – Early Trials toripalimab-tpzi + surufatinib Sensitive : C3
BRAF V600	Melanoma	BRAF V600	Melanoma	vemurafenib + toripalimab-tpzi Sensitive: C3 – Early Trials vemurafenib + toripalimab-tpzi Sensitive : C3	vemurafenib + toripalimab-tpzi Sensitive: C3 – Early Trials vemurafenib + toripalimab-tpzi Sensitive : C3
TP53 mutation	Biliary Tract Cancer	TP53 mutation	Biliary Tract Cancer	gemcitabine + toripalimab-tpzi Resistant: C3 – Early Trials gemcitabine + toripalimab-tpzi Resistant : C3	gemcitabine + toripalimab-tpzi Resistant: C3 – Early Trials gemcitabine + toripalimab-tpzi Resistant : C3

Loqtorzi (toripalimab-tpzi)

Associations
(88)

Associations
(88)

Loqtorzi (toripalimab-tpzi)

Associations(88)

Associations(88)

Associations
(88)

Associations
(88)